Health TrialsbyHealthPanel

Environmental Factors Associated With Peripheral Neuropathies in French Guiana

ConditionsPeripheral NeuropathiesEnvironmental Risk FactorLead NeuropathyMercury NeuropathyBita
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAdmin CIC

About this trial

Peripheral neuropathies (PN) affect 1% of the global population, particularly the elderly. About 20-30% of cases remain unexplained. In French Guiana, we hypothesize that factors like neurotoxic traditional plant remedies, arboviral disease outbreaks, and mercury exposure from illegal gold mining may contribute to PN. The study aims to assess the association between PN and exposure to arboviral infections, heavy metals, and plant consumption in French Guiana.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

For the Case group: patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy

For the Control group: patients hospitalized or consulting at the hospitals in Cayenne and Saint-Laurent du Maroni, without peripheral neuropathy.

Disqualifiers

For the Case and Control groups: patients under the age of 18, those who object to participation and those who are unable to complete the questionnaire.

Trial design

Design model

Single group

Treatments tested in this trial

  • Case Group

    Other intervention

    Patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy.

Treatment groups

78 Participants
are divided into 1 treatment group
Group A: Control groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Comparison of exposure rates among cases and controls

The primary endpoint will be the comparison of rates of exposure to arboviruses, heavy metals and consumption of potentially neurotoxic plants in cases and controls. The heavy metals assay and the questionnaire will be carried out at the inclusion visit.

Time frame
At inclusion

Secondary outcomes

1

Genetic mutations indentification

Secondary endpoint will be identification of genetic mutations responsible for peripheral neuropathy

Time frame
At inclusion
2

Peripheral Nerve Disability (PND) determination

Secondary endpoint will be determination of Peripheral Nerve Disability (PND)

Time frame
At inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Admin CIC

Lead sponsor

Centre Hospitalier de Cayenne

Sponsor institution

Source ClinicalTrials.gov
Apply now